Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Dipna Pharmachem's share price for the quarter that ended in Mar. 2026 was ₹8.02. Dipna Pharmachem's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 26 Mil. Therefore, Dipna Pharmachem's market cap for the quarter that ended in Mar. 2026 was ₹211 Mil.
Dipna Pharmachem's quarterly market cap
increased
from Mar. 2025 (₹344 Mil) to Sep. 2025 (₹483 Mil) but then
declined
from Sep. 2025 (₹483 Mil) to Mar. 2026 (₹211 Mil).
Dipna Pharmachem's annual market cap
increased
from Mar. 2024 (₹227 Mil) to Mar. 2025 (₹344 Mil) but then
declined
from Mar. 2025 (₹344 Mil) to Mar. 2026 (₹211 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Dipna Pharmachem's Enterprise Value for Today is ₹249 Mil.
Dipna Pharmachem (BOM:543594) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Dipna Pharmachem Market Cap Related Terms
Dipna Pharmachem Market Cap Historical Data
* Premium members only.
The historical data trend for Dipna Pharmachem's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's Market Cap distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Dipna Pharmachem's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem (BOM:543594) has a Market Cap of ₹129 Mil as of Aug. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Dipna Pharmachem and its competitors. According to the industry distribution chart, Dipna Pharmachem ranks #674 out of 692 companies in the Healthcare Providers & Services industry, placing it in the top 97.4%.
Is Dipna Pharmachem's Market Cap too high?
Dipna Pharmachem's current Market Cap is ₹129 Mil. Based on the distribution chart, Dipna Pharmachem ranks #674 out of 692 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dipna Pharmachem has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's Market Cap compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #674 out of 692 companies for Market Cap. This places Dipna Pharmachem in the lower half of its industry. The industry median Market Cap is 104.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 104.48, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Dipna Pharmachem and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 104.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current Market Cap is ₹129 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹9.16, compared to a current price of ₹4.89 — trading 46.6% below its estimated fair value. The current Market Cap is ₹129 Mil. Dipna Pharmachem's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current Market Cap is ₹129 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹4.89 is trading 46.6% below its estimated GF Value™ of ₹9.16.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
Market Cap: ₹129 Mil
GF Value™: ₹9.16 vs. price of ₹4.89 (46.6% below fair value)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
62GF Score
Get the complete analysis for BOM:543594
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
